Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO

LG Life Sciences147 enrolled

Overview

This clinical trial is conducted to determine the optimal dose of LD02GIFRO in improvement of gastrointestinal motility between each dose group by comparing the effectiveness and safety in patients undergoing colon resection.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

147

Conditions

Colon Resection _large Interstinal Surgery

Interventions

LD02GIFRODRUG

comparison of different dosages of drug

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≥ 20 years * Subject is scheduled for a partial colon resection with primary anastomosis via laparotomy * Subject is scheduled to receive primary postoperative pain management with intravenous patient-controlled analgesia (PCA) opioids Exclusion Criteria: * Subject is scheduled for a total colectomy, colostomy, ileostomy * Subject has complete bowel obstruction * Subject is scheduled for laparoscopic surgery

Locations (1)

Asan medical center

Seoul, South Korea

Outcomes

Primary Outcomes

Improvement of gastrointestinal motility

Evaluation gastrointestinal function to the time of improvement gastrointestinal motility

Time frame: in hospitalization (Maximized 14 days)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.